ABBV News 56.44 07/01/2014 04:21:58 Abbvie Inc. Common Stock
Post# of 273330
Posted On: 07/01/2014 5:21:53 AM
Abbvie Inc. Common Stock (ABBV) 56.44 $ABBV
Why Investors are Wrong about Gilead
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 30, 8:23PM CDT
Big biotech Gilead (Nasdaq: GILD) has gone on a tremendous 200% two year run as its groundbreaking hepatitis-C cure Sovaldi is breaking all expectations with $2.3 billion in just its first quarter of availability. This has led to nothing but...
Gilead Seeks Japanese Approval for Sovaldi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 4:11PM CDT
Gilead is looking to get Sovaldi approved in Japan.
AbbVie's Oncology Candidate Progresses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 3:45PM CDT
AbbVie Inc. (ABBV) announced that it has initiated a phase III study on its oncology candidate, veliparib.
Merger Monday: The AbbVie/Shire Saga Continues
Alex Dumortier, CFA, The Motley Fool - Motley Fool - Mon Jun 30, 9:19AM CDT
As we begin an abbreviated trading week due to the Independence Day holiday, U.S stocks are little changed on Monday morning, with the benchmark S&P 500 and the narrower Dow Jones Industrial Average up 0.14% and 0.08%, respectively, at 10:15...
European Stocks Are Mixed; Steady Inflation in Eurozone
at The Street - Mon Jun 30, 5:25AM CDT
European markets are mixed Monday after a relatively strong performance in Asia overnight.
Scheduled Conference Calls, License Agreements, Dividends, Preliminary Proxy statements and Initiation of Clinical Studies - Analyst Notes on Merck, Johnson & Johnson, AbbVie, Valeant and GSK
PR Newswire - Mon Jun 30, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), AbbVie Inc (NYSE: ABBV), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and GlaxoSmithKline plc (ADR) (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4237-100free.
Tax-Fleeing Takeover Mania Surges Forward
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat Jun 28, 12:17PM CDT
Health-care companies are increasingly looking to flee the U.S. for lower corporate tax rates and to access cash trapped overseas. While all deals will pale in comparison with Pfizer 's failed pursuit of AstraZeneca , that would-be deal has...
Shire Snubs AbbVie Offer Again, Favorable Ruling for Vyvanse - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 1:25PM CDT
Shire (SHPG) recently announced that it continues to maintain its stance against AbbVie (ABBV)'s acquisition offer.
3 Stocks Boosting The Health Care Sector Higher
at The Street - Thu Jun 26, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Closer Look at Gilead's Slowing Hep C Prescriptions
at The Street - Thu Jun 26, 9:23AM CDT
Is a slowdown in Sovaldi prescriptions the beginning of the highly anticipated "re-warehousing" of patients, or is some other factor at play?
AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) in Patients with Advanced Breast Cancer
PR Newswire - Thu Jun 26, 7:00AM CDT
AbbVie (NYSE: ABBV) today announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and paclitaxel, two chemotherapeutic medicines, in patients with advanced breast cancer. Specifically, the combination of veliparib, carboplatin and paclitaxel will be compared to treatment with carboplatin, paclitaxel and placebo in patients with human epidermal growth factor receptor 2-(HER2) negative metastatic or locally-advanced breast cancer, containing BRCA1 and/or BRCA2 gene mutations.
Stocks Hold Modest Gains; Shire Hits New High
at Investor's Business Daily - Wed Jun 25, 12:23PM CDT
Stocks continued to hold modest gains Wednesday afternoon after shaking off early losses caused by disappointing economic data. The Nasdaq and the S&P 500 were up 0.4% and 0.3%, respectively. Meanwhile, the Dow Jones industrial average was up 0.2%....
AbbVie cites tax break as a Shire deal motivator
By TOM MURPHY - AP - Wed Jun 25, 11:50AM CDT
U.S. drugmaker AbbVie sees a compelling tax break behind its roughly $46 billion bid to buy British counterpart Shire, and it expects the deal to expand Shire's global reach as well.
Why AbbVie (ABBV) Stock Is Gaining Today
at The Street - Wed Jun 25, 10:17AM CDT
Shares of AbbVie (ABBV) are up after the pharmaceuticals company presented its strategic rationale for acquiring Shire (SHPG).
Will Shire's Growth Plan Motivate AbbVie to Dig Deeper?
Cheryl Swanson, The Motley Fool - Motley Fool - Wed Jun 25, 8:30AM CDT
The market is already looking for AbbVie Inc to sweeten its recently rejected cash-and-shares offer of $46.5 billion for British drug maker Shire . But, by how much? And, assuming AbbVie comes up with yet another offer, will it be enough to...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
PR Newswire Europe - Wed Jun 25, 7:47AM CDT
- Materials for analyst and investor call in respect of possible offer for Shire plc
Why Investors are Wrong about Gilead
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 30, 8:23PM CDT
Big biotech Gilead (Nasdaq: GILD) has gone on a tremendous 200% two year run as its groundbreaking hepatitis-C cure Sovaldi is breaking all expectations with $2.3 billion in just its first quarter of availability. This has led to nothing but...
Gilead Seeks Japanese Approval for Sovaldi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 4:11PM CDT
Gilead is looking to get Sovaldi approved in Japan.
AbbVie's Oncology Candidate Progresses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 3:45PM CDT
AbbVie Inc. (ABBV) announced that it has initiated a phase III study on its oncology candidate, veliparib.
Merger Monday: The AbbVie/Shire Saga Continues
Alex Dumortier, CFA, The Motley Fool - Motley Fool - Mon Jun 30, 9:19AM CDT
As we begin an abbreviated trading week due to the Independence Day holiday, U.S stocks are little changed on Monday morning, with the benchmark S&P 500 and the narrower Dow Jones Industrial Average up 0.14% and 0.08%, respectively, at 10:15...
European Stocks Are Mixed; Steady Inflation in Eurozone
at The Street - Mon Jun 30, 5:25AM CDT
European markets are mixed Monday after a relatively strong performance in Asia overnight.
Scheduled Conference Calls, License Agreements, Dividends, Preliminary Proxy statements and Initiation of Clinical Studies - Analyst Notes on Merck, Johnson & Johnson, AbbVie, Valeant and GSK
PR Newswire - Mon Jun 30, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), AbbVie Inc (NYSE: ABBV), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and GlaxoSmithKline plc (ADR) (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4237-100free.
Tax-Fleeing Takeover Mania Surges Forward
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sat Jun 28, 12:17PM CDT
Health-care companies are increasingly looking to flee the U.S. for lower corporate tax rates and to access cash trapped overseas. While all deals will pale in comparison with Pfizer 's failed pursuit of AstraZeneca , that would-be deal has...
Shire Snubs AbbVie Offer Again, Favorable Ruling for Vyvanse - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 1:25PM CDT
Shire (SHPG) recently announced that it continues to maintain its stance against AbbVie (ABBV)'s acquisition offer.
3 Stocks Boosting The Health Care Sector Higher
at The Street - Thu Jun 26, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Closer Look at Gilead's Slowing Hep C Prescriptions
at The Street - Thu Jun 26, 9:23AM CDT
Is a slowdown in Sovaldi prescriptions the beginning of the highly anticipated "re-warehousing" of patients, or is some other factor at play?
AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) in Patients with Advanced Breast Cancer
PR Newswire - Thu Jun 26, 7:00AM CDT
AbbVie (NYSE: ABBV) today announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and paclitaxel, two chemotherapeutic medicines, in patients with advanced breast cancer. Specifically, the combination of veliparib, carboplatin and paclitaxel will be compared to treatment with carboplatin, paclitaxel and placebo in patients with human epidermal growth factor receptor 2-(HER2) negative metastatic or locally-advanced breast cancer, containing BRCA1 and/or BRCA2 gene mutations.
Stocks Hold Modest Gains; Shire Hits New High
at Investor's Business Daily - Wed Jun 25, 12:23PM CDT
Stocks continued to hold modest gains Wednesday afternoon after shaking off early losses caused by disappointing economic data. The Nasdaq and the S&P 500 were up 0.4% and 0.3%, respectively. Meanwhile, the Dow Jones industrial average was up 0.2%....
AbbVie cites tax break as a Shire deal motivator
By TOM MURPHY - AP - Wed Jun 25, 11:50AM CDT
U.S. drugmaker AbbVie sees a compelling tax break behind its roughly $46 billion bid to buy British counterpart Shire, and it expects the deal to expand Shire's global reach as well.
Why AbbVie (ABBV) Stock Is Gaining Today
at The Street - Wed Jun 25, 10:17AM CDT
Shares of AbbVie (ABBV) are up after the pharmaceuticals company presented its strategic rationale for acquiring Shire (SHPG).
Will Shire's Growth Plan Motivate AbbVie to Dig Deeper?
Cheryl Swanson, The Motley Fool - Motley Fool - Wed Jun 25, 8:30AM CDT
The market is already looking for AbbVie Inc to sweeten its recently rejected cash-and-shares offer of $46.5 billion for British drug maker Shire . But, by how much? And, assuming AbbVie comes up with yet another offer, will it be enough to...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
PR Newswire Europe - Wed Jun 25, 7:47AM CDT
- Materials for analyst and investor call in respect of possible offer for Shire plc
(0)
(0)